Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment

NCT ID: NCT02504060

Last Updated: 2015-07-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 720 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2017-07-31

Brief Summary

This study is a randomized double-blind placebo-controlled clinical trail to evaluate the clinical efficacy and safety of 1.1 chemical drugs N-acetyl-D-glucosamine on Chinese IBS-D patients coming from thirty- six centers in Chinese. 720 IBS-D patients (360 for treatment group, 360 for placebo group) in this research are accord with the Rome III diagnostic criteria, screening/import period pain intensity scores of the NRS(numerical rating scale) week mean value are 3.0 plus and the days which at least more than one time a stool type are 6 or 7 type over 2 days/week. Test cycle includes screening/import period (2 weeks), open treatment period (12 weeks), follow-up period (2 weeks). The main outcome measures are pain intensity (NRS score 11 point scale) and stool type ( Bristol type), and secondary endpoints included overall symptoms sensory scores, defecation frequency, abdominal distension, defecation urgency and quality of life parameters (IBS-QOL scale).

Conditions

Irritable Bowel Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Starch capsule

During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.

Group Type: PLACEBO_COMPARATOR

Starch Placebo

Intervention Type: DRUG

N-acetyl-D-glucosamine

During the 12- weeks treatment phase of the study, the daily dose of 100mg\*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.

Group Type: EXPERIMENTAL

N-acetyl-D-glucosamine

Intervention Type: DRUG

Interventions

Starch Placebo

Intervention Type: DRUG

N-acetyl-D-glucosamine

Intervention Type: DRUG

Other Intervention Names

Atysamine(ATSM)

Eligibility Criteria

Inclusion Criteria

• Voluntarily signed the informed consent form.
• Man or woman, aged 18 to 65 years, inclusive.
• Based on the Roman III diagnostic criteria for diagnosis of IBS-D subjects, recurrent abdominal pain accompanied with abdominal discomfort or not, monthly attack within the past 3months at least 3 days. With two or more of the following three kinds of symptoms:

At least a portion of the time abdominal pain or defecate increase when discomfort.

At least a portion of the time abdominal pain or the row of loose stools when discomfort.

At least a portion of the time abdominal pain or discomfort improved after defecation.

Symptoms for at least 6 months before diagnosis.

• Screening/import period pain intensity scores of the NRS week mean value are 3.0 plus and the days which at least more than one time a stool type are 6 or 7 type over 2 days per week.
• During the screening period，patients should answer the questions of electronic log completely following the requirements for 10days or more.
• Patients are willing to stop drugs for abdominal symptoms or diarrhea which are in violation of the scheme, and take medicine prescribed in the scheme.
• Patients agree to not change the lifestyle significantly that may affect the symptoms of IBS-D from signing up the Informed Consent Form to the last experiment.
• The illness recured after a normal colonoscopy report within one year that was provided by this hospital or a grade first class teaching hospital, include polyp of colon (less than 3mm,the number of less than 5) patients who taked therapeutic endoscopy and recurrenced within one year; or those that get a normal colonoscopy report in this hospital or a grade first class teaching hospital before screening but have a history of bowel preparation, should be chosen when next attack.

Exclusion Criteria

• History of organic gastrointestinal diseases: Chronic pancreatitis (cp), inflammatory bowel disease, intestinal tuberculosis, malabsorption syndrome, celiac disease, gastrointestinal tumor, or other organic diseases etc.
• History of abdominal and pelvic surgery ( not including appendectomy and intestinal polyposis (<3mm) after treatment within one year ).
• The non-intestinal disease of digestive system such as Peptic ulcer, tuberculous peritonitis, cirrhosis etc.
• Heart, lung, kidney and other important organs have severe lesions, immune regulatory disease, metabolic disease (diabetes, thyroid disease) or malignant tumor, reproductive system diseases such as ovarian cysts, endometriosis, etc.
• Laboratory tests or Electrocardiogram were significantly abnormal, and judging by the researchers may damage the patient safety or successful completion of the clinical research:

Male hemoglobin <120g/L, female hemoglobin <100g/L;

Male serum creatinine≥133umol/L, female serum creatinine≥124umol/L; or creatinine clearance rate≤60ml/min;

Chronic liver disease and/or abnormal liver function, defined as AST (aspartate aminotransferase) > 1.5 x ULN (Upper Limit Of Normal) and/or ALT (alanine aminotransferase) > 1.5 x ULN and/or total bilirubin > 1.5x ULN;

• Serious psychiatric patients( Hamilton Depression Scale scores>20).
• History of drug abuse or alcohol abuse.
• Allergic to this study drug.
• Concomitant medication is unable to stop or use continuously for more than a week but affect the gastrointestinal movement and function in the experiment, such as antibiotic drugs, the drugs of regulating the intestinal microecology, parasympathetic inhibitors, muscle relaxants, antidiarrheal, opiates, etc.
• Do not fill in the electronic log of one week before entering the group (-1 week) completely.
• Pregnant or lactating women
• Is participating in clinical trials or have finished it less than 3 months.
• Other researchers think not suitable for the list.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Third Military Medical University

OTHER

Sponsor Role: lead

Responsible Party

Liujunkang

The director of microecological pharmaceutical research

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Junkang Liu, Doctor

Role: STUDY_CHAIR

Third MMU

Locations

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Junkang Liu, Doctor

Role: CONTACT

liujunkang@163.com

+86-023-68752191

Yanxia Liu, Master

Role: CONTACT

liuyibin_04@163.com

+86-023-68752372

Facility Contacts

Xiaohua Hou, Doctor

Role: primary

yejin8688@sina.com

13035143646

Other Identifiers

dongying

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

TMMUBC

Identifier Type: -

Identifier Source: org_study_id